Ulcerative Colitis Clinical Trial
Struggling to manage your Ulcerative Colitis?
You may be eligible to participate in a clinical trial for a new treatment
Struggling to manage your Ulcerative Colitis? You may be eligible to participate in a clinical trial for a new treatment
Details for the study
Treatments and/or Procedures
Inclusion Criteria: - Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available. - Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points and endoscopic sub score of 2 to 3 (confirmed by central reader). - Demonstrated an inadequate response to, loss of response to, or intolerance to oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies. - If female, participant must meet the criteria for Contraception Recommendations. - Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing. Exclusion Criteria: - Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC). - Current diagnosis of fulminant colitis and/or toxic megacolon. - Participant with disease limited to the rectum (ulcerative proctitis) during the Screening endoscopy. - Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline. - Participant on azathioprine or 6-mercaptopurine within 10 days of baseline. - Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period. - Participant with previous exposure to JAK inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib). - Screening laboratory and other analyses show any abnormal results.